Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2005;31(2):75–89. doi: 10.1385/IR:31:2:075

Pulmonary defense and the human cathelicidin hCAP-18/LL-37

R J Fahy 1,✉, M D Wewers 1
PMCID: PMC7102303  PMID: 15778507

Abstract

Antimicrobial peptides form an important component of the innate immune system. The cathelicidin family, a key member of the antimicrobial peptide defenses, has been highly conserved throughout evolution. Though widespread in mammals, there is currently only one identified human example, hCAP-18/LL-37. The cathelicidins have been found to have multiple functions, in addition to their known antimicrobial and lipopolysaccharide-neutralizing effects. As a result, they profoundly affect both innate and adaptive immunity. Currently, antimicrobial peptides are being evaluated as therapeutic drugs in disease states as diverse as oral mucositis, cystic fibrosis, and septic shock. One such peptide, the cathelicidin hCAP-18/LL-37, is reviewed in detail in the context of its role in lung physiology and defense.

Key Words: Innate immunity, Antimicrobial peptides, Cathelicidin, LL-37, Lung

References

  • 1.Hackett C. Innate immune activation as a broad-spectrum biodefense strategy: prospects and research challenges. J Allergy Clin Immunol. 2003;112(4):686–694. doi: 10.1016/S0091-6749(03)02025-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fluhr R, Kaplan-Levy RN. Plant disease resistance: commonality and novelty in multicellular innate immunity. Curr Top Microbiol Immunol. 2002;270:23–46. doi: 10.1007/978-3-642-59430-4_2. [DOI] [PubMed] [Google Scholar]
  • 3.Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med. 2003;254(3):197–215. doi: 10.1046/j.1365-2796.2003.01228.x. [DOI] [PubMed] [Google Scholar]
  • 4.Ganz T. Defensins: antimicrobial peptides of innate immunity. Nature Rev Immunol. 2003;3(9):710–720. doi: 10.1038/nri1180. [DOI] [PubMed] [Google Scholar]
  • 5.Larrick JW, Hirata M, Balint RF, et al. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995;63(4):1291–1297. doi: 10.1128/iai.63.4.1291-1297.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gennaro R, Skerlavaj B, Romeo D. Purification, composition, and activity of two bactenecins, antibacterial peptides of bovine neutrophils. Infect Immun. 1989;57(10):3142–3146. doi: 10.1128/iai.57.10.3142-3146.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Basanez G, Shinnar AE, Zimmerberg J. Interaction of hagfish cathelicidin antimicrobial peptides with model lipid membranes. FEBS Lett. 2002;532(1–2):115–120. doi: 10.1016/S0014-5793(02)03651-7. [DOI] [PubMed] [Google Scholar]
  • 8.Gudmundsson GH, Agerberth B, Odeberg J, et al. The human gene FALL 39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238(2):325–332. doi: 10.1111/j.1432-1033.1996.0325z.x. [DOI] [PubMed] [Google Scholar]
  • 9.Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995;374(1):1–5. doi: 10.1016/0014-5793(95)01050-O. [DOI] [PubMed] [Google Scholar]
  • 10.Sorensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951–3959. doi: 10.1182/blood.V97.12.3951. [DOI] [PubMed] [Google Scholar]
  • 11.Sorensen OE, Gram L, Johnsen AH, et al. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem. 2003;278(31):28540–28546. doi: 10.1074/jbc.M301608200. [DOI] [PubMed] [Google Scholar]
  • 12.Sorensen O, Cowland JB, Askaa J, Borregaard N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods. 1997;206(1–2):53–59. doi: 10.1016/S0022-1759(97)00084-7. [DOI] [PubMed] [Google Scholar]
  • 13.Carlsson G, Fasth A. Infantile genetic agranulocytosis, morbus Kostmann: presentation of six cases from the original “Kostmann family” and a review. Acta Paediatr. 2001;90(7):757–764. doi: 10.1080/080352501750315663. [DOI] [PubMed] [Google Scholar]
  • 14.Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75(1):39–48. doi: 10.1189/jlb.0403147. [DOI] [PubMed] [Google Scholar]
  • 15.Marchini G, Lindow S, Brismar H, et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol. 2002;147(6):1127–1134. doi: 10.1046/j.1365-2133.2002.05014.x. [DOI] [PubMed] [Google Scholar]
  • 16.Sorensen O, Amljots K, Cowland JB, et al. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood. 1997;90(7):2796–2803. [PubMed] [Google Scholar]
  • 17.Nagaoka I, Hirata M, Sugimoto K, et al. Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow. J Leukoc Biol. 1998;64(6):845–852. doi: 10.1002/jlb.64.6.845. [DOI] [PubMed] [Google Scholar]
  • 18.Tomasinsig L, Scocchi M, Di Loreto C, et al. Inducible expression of an antimicrobial peptide of the innate immunity in polymorphonuclear leukocytes. J Leukoc Biol. 2002;72(5):1003–1010. [PubMed] [Google Scholar]
  • 19.Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151–1160. doi: 10.1056/NEJMoa021481. [DOI] [PubMed] [Google Scholar]
  • 20.Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A Streptococcus. J Invest Dermatol. 2001;117(1):91–97. doi: 10.1046/j.1523-1747.2001.01340.x. [DOI] [PubMed] [Google Scholar]
  • 21.Dorschner RA, Lin KH, Murakami M, Gallo RL. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res. 2003;53(4):566–572. doi: 10.1203/01.PDR.0000057205.64451.B7. [DOI] [PubMed] [Google Scholar]
  • 22.Wu H, Zhang G, Minton JE, et al. Regulation of cathelicidin gene expression: induction by lipopolysaccharide, interleukin-6, retinoic acid, and Salmonella enterica serovar typhimurium infection. Infect Immun. 2000;68(10):5552–5558. doi: 10.1128/IAI.68.10.5552-5558.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Larrick JW, Hirata M, Zheng H, et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol. 1994;152(1):231–240. [PubMed] [Google Scholar]
  • 24.Kirikae T, Hirata M, Yamasu H, et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun. 1998;66(5):1861–1868. doi: 10.1128/iai.66.5.1861-1868.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Scott MG, Davidson DJ, Gold MR, et al. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol. 2002;169(7):3883–3891. doi: 10.4049/jimmunol.169.7.3883. [DOI] [PubMed] [Google Scholar]
  • 26.Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol. 2004;172(2):1146–1156. doi: 10.4049/jimmunol.172.2.1146. [DOI] [PubMed] [Google Scholar]
  • 27.Niyonsaba F, Someya A, Hirata M, et al. Evaluation of the effects of peptide antibiotics human beta-defensins-1/−2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol. 2001;31(4):1066–1075. doi: 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  • 28.Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379–389. doi: 10.1046/j.1523-1747.2003.12069.x. [DOI] [PubMed] [Google Scholar]
  • 29.Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–2147. [PubMed] [Google Scholar]
  • 30.Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest. 2002;109(6):693–697. doi: 10.1172/JCI200215218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Liu L, Roberts AA, Ganz T. By IL-1 signaling, monocyte-derived cells damatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol. 2003;170(1):575–580. doi: 10.4049/jimmunol.170.1.575. [DOI] [PubMed] [Google Scholar]
  • 32.Perregaux DG, Bhavsar K, Contillo L, et al. Tntimicrobial peptides initiate IL-1 β posttranslational processing: a novel role beyond innate immunity. J Immunol. 2002;168(6):3024–3032. doi: 10.4049/jimmunol.168.6.3024. [DOI] [PubMed] [Google Scholar]
  • 33.Elssner A, Duncan M, Kotur M, et al. The human cathelicidin-derived peptide LL-37 induces secretion of IL-1 beta via transient ATP release and activation of the P2X receptor. J Immunol. 2003;172(8):4987–4994. doi: 10.4049/jimmunol.172.8.4987. [DOI] [PubMed] [Google Scholar]
  • 34.Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem. 1996;271(6):2935–2940. doi: 10.1074/jbc.271.6.2935. [DOI] [PubMed] [Google Scholar]
  • 35.Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 2000;96(9):3086–3093. [PubMed] [Google Scholar]
  • 36.De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192(7):1069–1074. doi: 10.1084/jem.192.7.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology. 2002;106(1):20–26. doi: 10.1046/j.1365-2567.2002.01398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665–1672. doi: 10.1172/JCI200317545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Turner J, Cho Y, Dinh NN, et al. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 1998;42(9):2206–2214. doi: 10.1128/aac.42.9.2206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Howell MD, Jones JF, Kisich KO, et al. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol. 2004;172(3):1763–1767. doi: 10.4049/jimmunol.172.3.1763. [DOI] [PubMed] [Google Scholar]
  • 41.Guthmiller JM, Vargas KG, Srikantha R, et al. Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob Agents Chemother. 2001;45(11):3216–3219. doi: 10.1128/AAC.45.11.3216-3219.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Henzler Wildman KA, Dong-Kuk L, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry. 2003;42(21):6545–6558. doi: 10.1021/bi0273563. [DOI] [PubMed] [Google Scholar]
  • 43.Travis SM, Anderson NN, Forsyth WR, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun. 2000;68(5):2748–2755. doi: 10.1128/IAI.68.5.2748-2755.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Saiman L, Tabibi S, Starner TD, et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45(10):2838–2844. doi: 10.1128/AAC.45.10.2838-2844.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sambri V, Marangoni A, Giacani L, et al. Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema pallidum. J Antimicrob Chemother. 2002;50(6):895–902. doi: 10.1093/jac/dkf220. [DOI] [PubMed] [Google Scholar]
  • 46.Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol. 2003;120(5):810–816. doi: 10.1046/j.1523-1747.2003.12132.x. [DOI] [PubMed] [Google Scholar]
  • 47.Shafer WM, Qu X, Waring AJ, Lehrer RI. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA. 1998;95(4):1829–1833. doi: 10.1073/pnas.95.4.1829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Lysenko ES, Gould J, Bals R, et al. Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun. 2000;68(3):1664–1671. doi: 10.1128/IAI.68.3.1664-1671.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Schmidtchen A, Frick IM, Andersson E, et al. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol. 2002;46(1):157–168. doi: 10.1046/j.1365-2958.2002.03146.x. [DOI] [PubMed] [Google Scholar]
  • 50.Islan D, Bandholtz L, Nilsson J, et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulaton. Nat Med. 2001;7(2):180–185. doi: 10.1038/84627. [DOI] [PubMed] [Google Scholar]
  • 51.Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol. 2003;28(6):738–745. doi: 10.1165/rcmb.2002-0191OC. [DOI] [PubMed] [Google Scholar]
  • 52.Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 1998;102(5):874–880. doi: 10.1172/JCI2410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Rennard S, Romberger D. Host defenses and pathogenesis. Semin Respir Infect. 2000;15(1):7–13. doi: 10.1053/srin.2000.0150007. [DOI] [PubMed] [Google Scholar]
  • 54.Canner P. Clearance of particles from the human tracheobronchial tree. Clin Sci (Lond) 1980;59(2):79–84. doi: 10.1042/cs0590079. [DOI] [PubMed] [Google Scholar]
  • 55.Welsh DA, Mason CM. Host defense in respiratory infections. Med Clin North Am. 2001;85(6):1329–1347. doi: 10.1016/S0025-7125(05)70383-7. [DOI] [PubMed] [Google Scholar]
  • 56.Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003;52(9):1–85. [PubMed] [Google Scholar]
  • 57.Travis SM, Conway BA, Zabner J, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol. 1999;20(5):872–879. doi: 10.1165/ajrcmb.20.5.3572. [DOI] [PubMed] [Google Scholar]
  • 58.Singh PK, Jia HP, Wiles K, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA. 1998;95(25):14961–14966. doi: 10.1073/pnas.95.25.14961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA. 1998;95(16):9541–9546. doi: 10.1073/pnas.95.16.9541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Remer KA, Brcic M, Jungi TW. Toll-like receptor-4 is involved in eliciting an LPS-induced oxidative burst in neutrophils. Immunol Lett. 2002;85(1):75–80. doi: 10.1016/S0165-2478(02)00210-9. [DOI] [PubMed] [Google Scholar]
  • 61.Netea MG, van der Graaf C, Van der Meer JWM, Jan-Kullberg B. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004;75(5):749–755. doi: 10.1189/jlb.1103543. [DOI] [PubMed] [Google Scholar]
  • 62.Lambrecht BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur Respir J. 2001;18(4):692–704. [PubMed] [Google Scholar]
  • 63.Sinigaglia F, D'Ambrosio D. Regulation of helper T cell differentiation and recruitment in airway inflammation. Am J Respir Crit Care Med. 2000;162(4):175S–160. doi: 10.1164/ajrccm.162.supplement_3.15tac3. [DOI] [PubMed] [Google Scholar]
  • 64.Woo JS, Jeong JY, Hwang YJ, et al. Expression of cathelicidin in human salivary glands. Arch Otolaryngol Head Neck Surg. 2003;129(2):211–214. doi: 10.1001/archotol.129.2.211. [DOI] [PubMed] [Google Scholar]
  • 65.van der Reijden WA, Vissink A, Veerman ECI, Amerongen AVN. Treatment of oral dryness related complaints (xerostomia) in Sjogren's syndrome. Ann Rheum Dis. 1999;58(8):465–474. doi: 10.1136/ard.58.8.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Dale BA, Kimball JR, Krisanaprakornkit S, et al. Localized antimicrobial peptide expression in human gingiva. J Periodontal Res. 2001;36(5):285–294. doi: 10.1034/j.1600-0765.2001.360503.x. [DOI] [PubMed] [Google Scholar]
  • 67.Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest. 1988;93(2):318–324. doi: 10.1378/chest.93.2.318. [DOI] [PubMed] [Google Scholar]
  • 68.Kim ST, Cha HE, Kim DY, et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol. 2003;123(1):81–85. doi: 10.1080/0036554021000028089. [DOI] [PubMed] [Google Scholar]
  • 69.Smith JJ, Travis SM, Greenberg E, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996;85(2):229–236. doi: 10.1016/S0092-8674(00)81099-5. [DOI] [PubMed] [Google Scholar]
  • 70.Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997;88(4):553–560. doi: 10.1016/S0092-8674(00)81895-4. [DOI] [PubMed] [Google Scholar]
  • 71.Kennedy MJ. Current status of gene therapy for cystic fibrosis pulmonary disease. Am J Respir Med. 2002;1(5):349–360. doi: 10.1007/BF03256628. [DOI] [PubMed] [Google Scholar]
  • 72.Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest. 1999;103(8):1113–1117. doi: 10.1172/JCI6570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med. 2002;165(7):992–995. doi: 10.1164/ajrccm.165.7.200110-020. [DOI] [PubMed] [Google Scholar]
  • 74.Agerberth B., Grunewald J, Castanos-Velez E, et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med. 1999;160(1):283–290. doi: 10.1164/ajrccm.160.1.9807041. [DOI] [PubMed] [Google Scholar]
  • 75.Repine JE. Interleukin-1-mediated acute lung injury and tolerance to oxidative injury. Environ Health Perspect. 1994;102(Suppl. 10):75–78. doi: 10.2307/3432219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Fahy RJ, Elssner A, Wewers MD. The antimicrobial peptide LL-37/hCAP-18 is elevated in early ARDS. Am J Respir Crit Care. Med. 2003;167(7):759–759. [Google Scholar]
  • 77.Toney JH. Iseganan (IntraBiotics pharmaceuticals) Curr Opin Invest Drugs. 2002;3(2):225–228. [PubMed] [Google Scholar]
  • 78.Cole AM, Waring AJ. The role of defensins in lung biology and therapy. Am J Respir Med. 2002;1(4):249–259. doi: 10.1007/BF03256616. [DOI] [PubMed] [Google Scholar]
  • 79.Warren HS, Matyal R, Allaire JE, et al. Protective efficacy of CAP18106-138-immunoglobulin G in sepsis. J Infect Dis. 2003;188(9):1382–1393. doi: 10.1086/379081. [DOI] [PubMed] [Google Scholar]
  • 80.Gennaro R, Scocchi M, Merluzzi L, Zanetti M. Biological characterization of a novel mammalian antimicrobial peptide. Biochim Biophys Acta. 1998;1425(2):361–368. doi: 10.1016/s0304-4165(98)00087-7. [DOI] [PubMed] [Google Scholar]
  • 81.Lusitani D, Malawista SE, Montgomery RR. Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J Infect Dis. 2002;185(6):797–804. doi: 10.1086/339341. [DOI] [PubMed] [Google Scholar]
  • 82.Larrick JW, Morgan JG, Palings I, et al. Complementary DNA sequence of rabbit CAP18: a unique lipopolysaccharide binding protein. Biochem Biophys Res Commun. 1991;179(1):170–175. doi: 10.1016/0006-291X(91)91350-L. [DOI] [PubMed] [Google Scholar]
  • 83.Nagaoka I, Hirota S, Niyonsaba F, et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-α by blocking the binding of LPS to CD14+Cells. J Immunol. 2001;167(6):3329–3338. doi: 10.4049/jimmunol.167.6.3329. [DOI] [PubMed] [Google Scholar]

Articles from Immunologic Research are provided here courtesy of Nature Publishing Group

RESOURCES